We are committed to revolutionizing the treatment of chronic asthma by providing a superior therapy that surpasses the current standard of care.

Our goal is to treat chronic asthma by using a patient's own genetically modified macrophages in which we eliminate the gene responsible for underlying lung chronic modifications.

We plan to collect blood from asthmatic patients, deplete PLA2G5 using CRISPR, and reinfuse autologous PLA2G5-deficient suppressive macrophages back into the same patient.

We are dedicated to providing safe, effective, and targeted treatment for asthma. Our approach not only addresses the underlying cause of the condition by reversing its inflammatory process but also focuses on restoring lung function.